Diagnostics & Research / Pharmaceutical Discovery Services
Strategic Profile
As a subsidiary of Eurofins Discovery Services LUX Holding SARL, Eurofins-Cerep is part of a larger group specializing in pharmaceutical discovery services. The company maintains a strong balance sheet with low debt and substantial cash reserves, positioning itself as a specialized provider in the pre-clinical drug research market.
Cyborg Score Rationale
The company experienced revenue decline of -7.51% in 2023 to €44.07 million and earnings decreased by -33.72%. However, gross margins of 43.18% and healthy financial ratios demonstrate operational stability, though the recent downward trajectory warrants caution.
Top Insights
Strong net cash position of €17.25 million with market cap of €91.80 million provides financial flexibility
Stock price declined -14.95% in last 52 weeks, indicating market pressure
Employs 228 people focused on specialized pre-clinical research services
Subsidiary structure within Eurofins group may provide operational synergies but limits strategic independence
Named Competitors
Drug Discovery Services — Integrated drug discovery and development services
Drug Discovery Services — Contract research and development services
Pre-clinical Research — Laboratory research services and models
Recent Developments
(2023) Revenue declined to €44.07 million with earnings down 33.72%
(2025) Market capitalization approximately €91.80 million with 52-week decline of -14.95%
(2025) Maintained strong gross margins of 43.18% despite revenue pressures
Open the full interactive Eurofins-Cerep SA report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.